{"id":391368,"date":"2015-06-30T00:00:00","date_gmt":"2015-06-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus2215-biopharma-breaking-up-is-hard-to-do-physician-payer-forum-us-2015\/"},"modified":"2026-04-22T05:27:40","modified_gmt":"2026-04-22T05:27:40","slug":"pforus2215-biopharma-breaking-up-is-hard-to-do-physician-payer-forum-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus2215-biopharma-breaking-up-is-hard-to-do-physician-payer-forum-us-2015\/","title":{"rendered":"Breaking Up Is Hard to Do | Physician &#038; Payer Forum | US | 2015"},"content":{"rendered":"<p><em>How Will the Availability of Generic Antiretrovirals Impact the Uptake of Branded Single-Tablet Regimens in the United States? <\/em><\/p>\n<p>The availability of once-daily single-tablet regimens (STRs) with high efficacy and good safety profiles has transformed HIV into a manageable chronic illness for most patients. However, the need for expensive, daily, lifelong antiretroviral (ARV) therapy can place a considerable cost burden on insurance providers. As a result, the eminent availability of generic versions of components in heavily prescribed regimens may force prescribing physicians to \u201cbreak up\u201d STRs and shift prescriptions to multi-tablet regimens (MTRs) that incorporate generics.<\/p>\n<p>This <em>U.S. Physician &#038; Payer Forum<\/em> report explores dynamics that impact uptake of current and emerging ARV agents used for the management of HIV infections. In particular, this report assesses what impact, if any, payer-imposed cost-containment measures will have on physician uptake of branded STRs and other premium-priced ARV agents. In addition to the treatment of HIV infections, this report delves into physician use of Gilead\u2019s Truvada (emtricitabine\/tenofovir disoproxil fumarate [TDF]) as pre-exposure prophylaxis (PrEP) for the prevention of HIV infection. Truvada is currently the only FDA-approved ARV agent for use as PrEP. Our findings are based on survey responses from U.S. infectious disease (ID) specialists and U.S. managed care organization (MCO) pharmacy directors\/medical directors (PDs\/MDs).<\/p>\n","protected":false},"template":"","class_list":["post-391368","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-infectious-disease","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391368\/revisions"}],"predecessor-version":[{"id":576953,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391368\/revisions\/576953"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}